<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468492</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #01979/FDA IDE#15944</org_study_id>
    <nct_id>NCT02468492</nct_id>
  </id_info>
  <brief_title>Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical &amp; Imaging Outcome Correlation</brief_title>
  <official_title>Synovial Fluid Biomarker and Mesenchymal Stem Cell Response to PRP in Knee Osteoarthritis With Clinical and Imaging Outcome Correlation: Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter Holmes Mcguire Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Physical Medicine and Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunter Holmes Mcguire Veteran Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the affect that platelet rich plasma has on the&#xD;
      molecular an cellular functioning of the knee joint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study 18 subjects with mild to moderate symptomatic knee osteoarthritis will be&#xD;
      recruited per an IRB approved protocol with explicit inclusion and exclusion criteria.&#xD;
      Subjects who are enrolled and meet all criteria will be blinded and randomized (2:1) to&#xD;
      receive Platelet Rich Plasma or normal saline &quot;control&quot;. Prior to the intervention, a&#xD;
      synovial fluid aspiration will occur. At follow up number one (approximately 10 days from&#xD;
      baseline) a repeat aspiration will occur and a differential analysis of the molecular and&#xD;
      biochemical effects will be undertaken; this data will serve as the primary outcome measures.&#xD;
      This data will be correlated to clinical and imaging outcome measures which will be secondary&#xD;
      outcome measures completed at baseline and intermittently throughout the study. The duration&#xD;
      of the study is one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Molecular Outcomes</measure>
    <time_frame>Baseline and 10 day follow up</time_frame>
    <description>Evaluate for change in biochemical molecular milieu temporal response after PRP injection or normal saline (control) compared to baseline, as measured by multiplex suspension array technology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation for change in pain level via VAS and WOMAC at baseline and follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation for change in joint space width using knee radiographs at baseline and 6 month follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 5mL of intraarticular PRP once at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Approximately 5mL of intraarticular normal saline once at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich Plasma</intervention_name>
    <description>Platelet rich plasma injection into knee versus placebo (saline) injection.</description>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <other_name>Platelet Concentrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Platelet rich plasma injection into knee versus placebo (saline) injection.</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Early/Mild to Moderate Stage knee osteoarthritis (KOA), as determined by&#xD;
             Kellgren-Lawrence Grade 2 to 3 on PA standing radiograph within the past three months;&#xD;
&#xD;
               -  A prospective subject who has a diagnosis of non-end stage KOA (i.e., a potential&#xD;
                  study candidate) and expresses interest in participating but has no XRAY within&#xD;
                  the specified time-period will be sent for a fresh XRAY. This XRAY will be read&#xD;
                  by a radiologist &amp; be paid for by the study.&#xD;
&#xD;
          2. &gt;=40 years of age;&#xD;
&#xD;
          3. Average 100-point VAS score of &gt;50, on average, within the past 3 months*, with KOA&#xD;
             felt to be the primary contributor to pain.&#xD;
&#xD;
               -  Alternate 10-point scales with pain scores averaging &gt;5 may be considered if the&#xD;
                  prospective subject also completes a VAS with score &gt;50 at screening.&#xD;
&#xD;
          4. Exam consistent with KOA being primary etiology of pain;&#xD;
&#xD;
          5. No signs of inflammatory arthropathy in medical record, history or physical&#xD;
             examination;&#xD;
&#xD;
          6. A &gt;3 millimeter intra-articular (IA) effusion present on ultrasound evaluation.&#xD;
&#xD;
          7. [If a chronic liver or renal disease patient, evidence of stable disease over/within&#xD;
             the past six months, else exclusion.]&#xD;
&#xD;
          8. Veteran receiving care at McGuire VAMC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Morbid obesity (BMI &gt;40);&#xD;
&#xD;
          2. Poorly controlled diabetes (hemoglobin A1C &gt; 7.5 or fasting blood glucose of &gt;200) in&#xD;
             last 6 months;&#xD;
&#xD;
          3. Ipsilateral knee surgery, trauma within last 6 months, or corticosteroid injection&#xD;
             within 3 months.&#xD;
&#xD;
          4. 4. History of inflammatory arthropathy (RA, SLE or crystalline arthritis of the&#xD;
             knee)**;&#xD;
&#xD;
          5. Any rheumatoid arthritis or gout diagnosis is exclusionary.&#xD;
&#xD;
          6. Current infection of the affected joint or any other uncontrolled or untreated active&#xD;
             infection.&#xD;
&#xD;
          7. Moderate to severe anemia (hemoglobin &lt; 11 g/dl) or thrombocytopenia (platelet count &lt;&#xD;
             100,000); Hemoglobin &gt;17 g/dl or &lt;11 g/dl and/or platelet counts &gt;500,000 or &lt;100,000&#xD;
             platelets/Î¼l.&#xD;
&#xD;
               -  [CBC obtained within 6 months will be required, even if obtained at initial&#xD;
                  screening visit.]&#xD;
&#xD;
          8. Individuals on dialysis, with liver failure, or uncontrolled renal or liver disease&#xD;
             are excluded.&#xD;
&#xD;
               -  In those with chronic renal or liver disease, documentation of stable disease&#xD;
                  within the most recent 6 months will be required.&#xD;
&#xD;
          9. Individuals on a therapeutic anticoagulant (e.g., Warfarin, Dabigatran, Enoxaparin)&#xD;
             and those with a history of coagulopathy are excluded.&#xD;
&#xD;
               -  Per standard clinical practice, subjects on anti-platelet therapy are not&#xD;
                  excluded.&#xD;
&#xD;
         10. Pregnancy or breast-feeding;&#xD;
&#xD;
               -  Female subjects of child-bearing potential must have a negative pregnancy screen&#xD;
                  prior to enrollment.&#xD;
&#xD;
               -  Female subjects of child-bearing potential must confirm they are not actively&#xD;
                  breast-feeding prior to enrollment.&#xD;
&#xD;
         11. Current illicit drug abuse / active alcohol abuse (i.e, Current substance abuse);&#xD;
&#xD;
         12. Uncontrolled psychiatric disorder;&#xD;
&#xD;
         13. Lack of transportation (i.e., to get to/from appointments at VAMC) and/or willingness&#xD;
             to attend study appointments (screening/consent, Intervention, Day10-follow-up,&#xD;
             Month-6 follow-up, and then visits over-the-phone / in-person / or via Telehealth for&#xD;
             Month-3 and Month-12;&#xD;
&#xD;
         14. Advanced or currently active cancer.&#xD;
&#xD;
         15. Blood disorders (such as Sickle Cell Anemia, TTP, others)&#xD;
&#xD;
         16. Vulnerable populations: Individuals incapable of making informed decisions will not be&#xD;
             enrolled, nor will those under some form of incarceration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lance L Goetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunter Holmes McGuire VAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 31, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>August 13, 2017</last_update_submitted>
  <last_update_submitted_qc>August 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunter Holmes Mcguire Veteran Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Lance Goetz</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Platelet Rich Plasma</keyword>
  <keyword>Mechanism of Action</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Synovial Fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Publications planned.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

